Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kura Oncology IncfiledCriticalKura Oncology Inc
Publication of AR109498A1publicationCriticalpatent/AR109498A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Reivindicación 1: Un método de tratar cáncer en un sujeto que así lo necesite, caracterizado porque comprende administrar una dosis eficaz de un inhibidor de una quinasa regulada por señales extracelulares (ERK) al sujeto, en donde dicho sujeto comprende un genoma que exhibe amplificación y/o sobreexpresión de por lo menos un gen que se localiza en el cromosoma 11q13.3-13.4.Claim 1: A method of treating cancer in a subject in need thereof, characterized in that it comprises administering an effective dose of an extracellular signal-regulated kinase inhibitor (ERK) to the subject, wherein said subject comprises a genome that exhibits amplification and / or overexpression of at least one gene that is located on chromosome 11q13.3-13.4.
ARP170101684A2016-06-202017-06-19
TREATMENT OF SCALE CARCINOMAS WITH ERK INHIBITORS
AR109498A1
(en)